Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response Fleischmann, R., Genovese, M., Blanco, R., Hall, S., Thomson, G., Van den Bosch, F., Zerbini, C. A., Enejosa, J., Li, Y., DeMasi, R., Song, I. WILEY. 2019

View details for Web of Science ID 000507466905137